Glooko continues to carve out a niche in the mobile diabetes management space.
Since opening its doors 3 years ago, the Silicon Valley-based mHealth company has landed multiple FDA wins for both the Android and Apple smartphone operating systems, partnerships with industry giants such as Roche (PINK:RHHBY) and WalMart for its ReliOn meter, and a growing base of patient users and healthcare provider subscribers.
In this MassDevice.com podcast, we speak with CEO Rick Altinger ahead of his appearance at the upcoming MassDevice Big 100 West in Irvine, Calif., Dec. 10 to get his take on Glooko’s future, how it fits into the current diabetes spectrum and why the company’s model could be used to treat other forms of chronic diseases.
Hear Rick Altinger discuss the future of chronic diseases at the MassDevice Big 100 West
"We liberate the data from the glucose meter into the platform the patient wants, their smartphone, and then we put it in the cloud and do analytics on that data," Altinger tells us. "It’s disruptive to how diabetes is managed. It’s about allowing us in the industry to focus more on management than on measurement. It’s about management and doing something with that data, rather than just measuring it."
